TITLE

ONTARIO DRUG PLAN NOW COVERS EXELON FOR ALZHEIMER

PUB. DATE
April 2001
SOURCE
Worldwide Biotech;Apr2001, Vol. 13 Issue 4, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the decision of the government of Ontario to include Exelon, a symptomatic treatment for Alzheimer Disease, on the Ontario Drug Benefit Formulary as a Limited Use Benefit effective March 7, 2001.
ACCESSION #
4299812

 

Related Articles

  • Tech startup of the month: ACCERA INC., AURORA. Peterson, Eric // ColoradoBiz;Jun2003, Vol. 30 Issue 6, p34 

    Assesses the efficacy of the Accera drug in treating patients with Alzheimer's disease in Colorado. Side effects of the drug; Reduction of cerebral metabolism among older patients; Symptoms of the disease.

  • Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein. M. Pakaski; P. Kasa // Current Drug Targets - CNS & Neurological Disorders;Jun2003, Vol. 2 Issue 3, p163 

    Potentiation of central cholinergic activity has been proposed as a therapeutic approach for improving the cognitive function in patients with Alzheimer's disease (AD). Increasing the acetylcholine concentration in the brain by modulating acetylcholine-sterase (AChE) activity is among the most...

  • Keeping current on Alzheimer's disease. Kelley, Roger E.; D'Epiro, Peter // Patient Care;6/15/1999, Vol. 33 Issue 11, p127 

    Focuses on drugs that may aid in the timely identification of patients at risk for Alzheimer's disease (AD). Available therapies that may delay disease onset and progression; Diagnostic assessment; Cholinomimetic therapy; Antidepressant therapy; Use of nonsteroidal anti-inflammatory drugs;...

  • Focus on donepezil. Lipson, Loren G.; Rho, Jay P.; Chow, Moses S.S. // Formulary;Jul97, Vol. 32 Issue 7, p677 

    Provides information on the drug Donepezil HCl approved by the Food and Drug Administration for the treatment of Alzheimer's disease. Chemistry and pharmacology of the drug; Pharmacokinetics; Result of the clinical trials conducted on the drugs; Adverse effects of the drug; Dosing and...

  • Drug watch: Alzheimer's disease.  // Formulary;May99, Vol. 34 Issue 5, p470 

    Lists drugs for Alzheimer's disease with their proposed formulation and status given by the Food and Drug Administration in the United States. Includes galanthamine; Lazabemide; Memantine; SB202026; Propentofylline; Rivastigmine; Olanzapine; Selegiline; Tacrine; AF-102B; Metrifonate;...

  • US row over Alzheimer's drug. Charatan, Fred // BMJ: British Medical Journal (International Edition);4/13/91, Vol. 302 Issue 6781, p870 

    Focuses on the development of tetrahydroaminoacridine for Alzheimer's disease in the United States. Approval of the drug; Effect of the drug to the public; Possibility of serious liver damage.

  • Business Update: INFORMATION AND RESOURCES.  // Medical Marketing & Media;Jan2002, Vol. 37 Issue 1, p90 

    Reports developments on drugs as of January 2002. Objectives of several pharmaceutical programs; Top pharmaceutical companies; Use of donepezil drug in treating patients with alzheimer's disease.

  • Novel Therapeutics in Alzheimer's Disease. Sabbagh, Marwan; Porsteinsson, Anton P.; Nair, Anil; Adem, Abdu // International Journal of Alzheimer's Disease;2012, p1 

    An introduction is presented in which the editors discuss various papers within the issue on topics including centella asiatica extract to enhance nerve function, immunotherapies for the treatment of Alzheimer's disease (AD), and acetylcholinesterase inhibitors as symptomatic treatments for AD.

  • Efficacy of FPF 1070 (Cerebrolysin) in Patients with Alzheimer's Disease: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Shifu, X.; Heqin, Y.; Peifen, Y. // Clinical Drug Investigation;2000, Vol. 19 Issue 1, p43 

    Objective: This study evaluated the efficacy and tolerability of FPF 1070 (cerebrolysin) in patients with mild to moderately severe Alzheimer's disease (AD). Methods: The trial was of a multicentre, double-blind, parallel-group design. 157 patients aged 55 to 85 years were randomised to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics